TriangleZilovertamab vedotin (NCT06890884)
Zilovertamab vedotin trial for Lymphoma, Large B-Cell, Diffuse (NCT06890884). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, PET-positive, germinal-center B-cell-type diffuse large B-cell lymphoma, stages II–IV. Transformed lymphoma, primary mediastinal lymphoma and grey-zone lymphoma are excluded.
The idea: compare zilovertamab vedotin, targeting ROR1, with polatuzumab vedotin, targeting CD79B. Both deliver cell-killing payloads. Each is combined with rituximab, cyclophosphamide, doxorubicin and prednisone or prednisolone. Randomized treatment lasts up to six three-week cycles; high-risk patients receive two additional rituximab cycles. Researchers compare complete responses and safety. Treatment includes infusions and oral steroids.
This phase 2 study plans 594 patients. Merck sponsors seventy-one recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.